TSXV:CLAS.H - Post by User
Post by
WORKINMONTANAon May 01, 2018 10:38am
![](https://assets.stockhouse.com/kentico-cms/0341-00/images/Sprite.svg#id_Post_Views_Icon)
112 Views
Post# 27964040
We Expect Our Phase 3 Study to Start Later this Year
We Expect Our Phase 3 Study to Start Later this Year KALYTERA THERAPEUITCS Letter to Shareholders Why is the market sleeping on this?
We are a Leader in the Field – We Expect Our Phase 3 Study to Start Later this Year
Our program evaluating CBD in the prevention of graft versus host disease (“GVHD”) is in late-stage clinical testing, and we have scheduled a meeting with the FDA’s Division of Hematology Projects to obtain consent to initiate a Phase 3 pivotal registration study in treatment of acute GVHD later this year.